Colchicine and COVID-19.

We read with interest the Letter to the Editor titled “Can Colchicine as an Old Anti‐Inflammatory Agent Be Effective in COVID‐19?” by Nasiripour et al., in which the authors stated that only 1 phase 3 multicenter, randomized, double‐blind, placebo‐controlled multicenter study has been assigned to clinicaltrials.gov by the Montreal Heart Institute to investigate the efficacy and safety of colchicine in adult patients diagnosed with COVID‐19.

In Argentina, we started COLCOVID Trial to test the effects of colchicine on moderate‐/high‐risk hospitalized COVID‐19 patients with the aim of reducing mortality. This study is a phase 3 multicenter, controlled trial; our protocol was published in ClinicalTrial.gov on March 31, 2020.

Therefore, we would like to affirm that, besides the COLCORONA Trial, there is another study ongoing focused on colchicine in COVID‐19.

We appreciate the opportunity to express our comment following the recent publication of the potential role of colchicine in SARS‐CoV‐2 infection.

Conflicts of Interest

Pablo Corral reports honoraria for lectures from Amgen, Sanofi, AstraZeneca, and PTC; research grants from Amgen and Genzyme, and personal fees for consultancy from Amgen, Novartis, and Sanofi. Rafael Diaz reports research grants from Sanofi, DalCor, Population Health Research Institute, Duke Clinical Research Institute, the TIMI group, Amgen, Cirius, Montreal Health Innovations Coordinating Center, and Lepetit and personal fees from Amgen and Cirius.